220 related articles for article (PubMed ID: 24414535)
1. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.
Gurney JG; Bass JK; Onar-Thomas A; Huang J; Chintagumpala M; Bouffet E; Hassall T; Gururangan S; Heath JA; Kellie S; Cohn R; Fisher MJ; Panandiker AP; Merchant TE; Srinivasan A; Wetmore C; Qaddoumi I; Stewart CF; Armstrong GT; Broniscer A; Gajjar A
Neuro Oncol; 2014 Jun; 16(6):848-55. PubMed ID: 24414535
[TBL] [Abstract][Full Text] [Related]
2. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.
Fouladi M; Chintagumpala M; Ashley D; Kellie S; Gururangan S; Hassall T; Gronewold L; Stewart CF; Wallace D; Broniscer A; Hale GA; Kasow KA; Merchant TE; Morris B; Krasin M; Kun LE; Boyett JM; Gajjar A
J Clin Oncol; 2008 Aug; 26(22):3749-55. PubMed ID: 18669462
[TBL] [Abstract][Full Text] [Related]
3. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
Bass JK; Huang J; Onar-Thomas A; Chang KW; Bhagat SP; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Heath JA; McCowage G; Cohn RJ; Fisher MJ; Robinson G; Broniscer A; Gajjar A; Gurney JG
Pediatr Blood Cancer; 2014 Apr; 61(4):601-5. PubMed ID: 24504791
[TBL] [Abstract][Full Text] [Related]
4. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
5. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
6. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
7. Prevention of hearing loss in children receiving cisplatin chemotherapy.
Freyer DR; Sung L; Reaman GH
J Clin Oncol; 2009 Jan; 27(2):317-8; author reply 318-9. PubMed ID: 19064953
[No Abstract] [Full Text] [Related]
8. Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma.
Lafay-Cousin L; Purdy E; Huang A; Cushing SL; Papaioannou V; Nettel-Aguirre A; Bouffet E
Pediatr Blood Cancer; 2013 Feb; 60(2):287-92. PubMed ID: 23002030
[TBL] [Abstract][Full Text] [Related]
9. Amifostine protects against cisplatin-induced nephrotoxicity in a child with medulloblastoma.
Hayek M; Srinivasan A
Pediatr Hematol Oncol; 2003; 20(3):253-6. PubMed ID: 12637222
[No Abstract] [Full Text] [Related]
10. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy.
Fisher MJ; Lange BJ; Needle MN; Janss AJ; Shu HK; Adamson PC; Phillips PC
Pediatr Blood Cancer; 2004 Dec; 43(7):780-4. PubMed ID: 15390300
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma.
Musial-Bright L; Fengler R; Henze G; Hernáiz Driever P
Childs Nerv Syst; 2011 Mar; 27(3):407-13. PubMed ID: 20931205
[TBL] [Abstract][Full Text] [Related]
12. Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma.
Paulino AC; Lobo M; Teh BS; Okcu MF; South M; Butler EB; Su J; Chintagumpala M
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1445-50. PubMed ID: 20231075
[TBL] [Abstract][Full Text] [Related]
13. Platinum-induced hearing loss after treatment for childhood cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010181. PubMed ID: 27486906
[TBL] [Abstract][Full Text] [Related]
14. Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children's Oncology Group.
Nageswara Rao AA; Wallace DJ; Billups C; Boyett JM; Gajjar A; Packer RJ
Pediatr Blood Cancer; 2014 Jan; 61(1):102-6. PubMed ID: 23956184
[TBL] [Abstract][Full Text] [Related]
15. Prevention of cisplatin-induced hearing-loss by sodium thiosulfate in medulloblastoma.
Harao T; Yamada A; Kinoshita M; Kamimura S; Moritake H
Pediatr Int; 2020 Oct; 62(10):1204-1206. PubMed ID: 32989850
[No Abstract] [Full Text] [Related]
16. Hearing loss in pediatric cancer survivors treated with cisplatin.
Knight K
Oncology (Williston Park); 2008 Apr; 22(4 Suppl Nurse Ed):35-7. PubMed ID: 19856560
[No Abstract] [Full Text] [Related]
17. SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma.
Brown AL; Lupo PJ; Okcu MF; Lau CC; Rednam S; Scheurer ME
Cancer Med; 2015 Nov; 4(11):1679-86. PubMed ID: 26400460
[TBL] [Abstract][Full Text] [Related]
18. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group.
Katzenstein HM; Chang KW; Krailo M; Chen Z; Finegold MJ; Rowland J; Reynolds M; Pappo A; London WB; Malogolowkin M;
Cancer; 2009 Dec; 115(24):5828-35. PubMed ID: 19813275
[TBL] [Abstract][Full Text] [Related]
19. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
Freyer DR; Chen L; Krailo MD; Knight K; Villaluna D; Bliss B; Pollock BH; Ramdas J; Lange B; Van Hoff D; VanSoelen ML; Wiernikowski J; Neuwelt EA; Sung L
Lancet Oncol; 2017 Jan; 18(1):63-74. PubMed ID: 27914822
[TBL] [Abstract][Full Text] [Related]
20. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected.
Schmidt CM; Knief A; Lagosch AK; Deuster D; am Zehnhoff-Dinnesen A
Ear Hear; 2008 Dec; 29(6):830-7. PubMed ID: 18772725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
